ライフサイエンスコーパス: single-chain antibody

1 nst human p53, have been used to construct a single-chain antibody.

2 otherapy for HIV-1 using novel CARs based on single-chain antibodies.

3 -binding regions of the microcystin-specific single-chain antibody, 3A8, with constant regions from t

4 ha-syn::GFP was reduced by immunization with single chain antibodies against alpha-syn.

5 These results indicate that such chimeric single-chain antibodies against IGF1R have future potent

6 via a recombinant fusion protein combining a single-chain antibody against activated glycoprotein IIb

7 es Edmonston-NSe vaccine strain displaying a single-chain antibody against EGFRvIII at the COOH termi

8 pendent methods, expression of intracellular single-chain antibody against HER-2 and treatment with a

9 We have previously shown that a chimeric single-chain antibody against IGF1R (scFv-Fc) and a muri

10 using three carbohydrate-binding proteins, a single chain antibody, an antigen binding fragment, and

11 on solutions containing a target protein (a single chain antibody, an antigen binding fragment, or a

12 Using a panel of single-chain antibodies and a single-chain T-cell recept

13 MegAnneal libraries based on three different single-chain antibodies and identified variants with enh

14 tely 100 million secreted and membrane-bound single-chain antibodies and identify antibodies that can

15 VHH nanobodies, or single-chain antibodies, are the variable domain, VH(H),

16 e delivery of NUsc1 or other AbetaO-specific single-chain antibodies as a potential therapeutic appro

17 hile chimeric antigen receptors (CARs) using single-chain antibodies as binding domains are growing i

18 ould be useful in improving the stability of single-chain antibodies, as Ala/Met mutations at these c

19 een the antigen and a panel of small, 25 kDa single-chain antibodies at concentrations down to 1 nM.

20 This stable single chain antibody based heterodimer has simplified t

21 BNAbs varying in binding sites and generated single-chain-antibody-based CARs.

22 ge, complex domains (either a 252-amino-acid single-chain antibody binding domain [scFv] or a 96-amin

23 also be achieved using a retroviral receptor-single-chain antibody bridge protein, the TVA-MR1 fusion

24 here the development of a novel, bispecific single-chain antibody (bscAb) referred to as bscEphA2xCD

25 roperties are comparable to those for stable single-chain antibodies, but are markedly improved over

26 orted earlier the delivery of antiangiogenic single chain antibodies by using oncolytic vaccinia viru

27 self-assembled nanorings (CSANs) displaying single chain antibodies can bind to both the CD3 epsilon

28 ed a membrane-tethered anti-Igkappa-reactive single chain antibody chimeric gene and expressed it as

29 A humanized single-chain antibody component in which the variable do

30 mbinant proteins, and describe a new type of single chain antibody containing the entire heavy chain

31 ced Binding Site (LIBS-MBs) or a nonspecific single-chain antibody (control MBs).

32 of the FSTE with a growth factor ligand or a single-chain antibody, delivered a reporter gene selecti

33 c avenue is represented by nanobodies, small single-chain antibodies derived from camelids with numer

34 Recognition of GD2 was provided by a single-chain antibody derived from the GD2-specific mono

35 ach requires development of a high-affinity, single chain antibody directed specifically against the

36 ticles of iron oxide (MPIOs) conjugated to a single-chain antibody directed against a ligand-induced

37 A single-chain antibody directed against IGF1R (IGF1R scFv

38 ately 5 nM) and specific localization to the single-chain antibody expressed in the endoplasmic retic

39 f chimeric antigen receptors (CARs) based on single-chain antibodies for gene immunotherapy of cancer

40 The 4M5.3 anti-fluorescein single chain antibody fragment (scFv) contains 14 mutati

41 mor targeting of a novel internalizing human single chain antibody fragment (scFv) labeled with ((9)(

42 lular expression of an inhibitory anti-ATF-1 single chain antibody fragment (ScFv).

43 llular expression of an inhibitory anti-ATF1 single chain antibody fragment (scFv4).

44 Here we show that a single chain antibody fragment (syn-10H scFv) isolated f

45 A single-chain antibody fragment (anti-1F12 scFv) was isol

46 alian cell line that expresses a recombinant single-chain antibody fragment (scFv) derived from an NS

47 Here, we used a single-chain antibody fragment (scFv) derived from the a

48 nes with an adenovirus (AV1Y28) expressing a single-chain antibody fragment (scFv) directed against R

49 f a hypothesis-driven mathematical model for single-chain antibody fragment (scFv) folding in Sacchar

50 h the corresponding conventional ER-targeted single-chain antibody fragment (scFv) intrabodies demons

51 We designed a supercharged single-chain antibody fragment (scFv) to enable a full l

52 cluster of differentiation 3 (CD3)-specific single-chain antibody fragment (scFv), effectively redir

53 A prostate tumor-targeting single-chain antibody fragment (scFv), UA20, along with

54 body to its minimal functional unit (i.e., a single-chain antibody fragment [scFv]) is an effective s

55 of the AV1Y28 adenovirus, which expresses a single-chain antibody fragment directed against p21 Ras

56 sults demonstrate that the topically applied single-chain antibody fragment ESBA105 penetrated into t

57 By using a single-chain antibody fragment isolated from a bacteriop

58 splay-enriched libraries, and high-picomolar single-chain antibody fragment leads for human interleuk

59 ral vector was used to deliver a recombinant single-chain antibody fragment rabbit intrabody (pAd-2S0

60 or a large language model that generated new single-chain antibody fragment sequences with higher aff

61 ding and antigen-binding activity of a human single-chain antibody fragment were simultaneously impro

62 topic expression of an inhibitory anti-ATF-1 single-chain antibody fragment, ScFv, significantly inte

63 Here we show that single chain antibody fragments (scFv's) isolated from n

64 We were able to isolate single chain antibody fragments (scFvs) from a phage dis

65 ant antivenom composed of a few neutralizing single chain antibody fragments (scFvs) that bind to two

66 is intermediate in size between peptides and single chain antibody fragments, both of which are super

67 Here we develop single-chain antibody fragments (nanobodies) against tub

68 We have produced single-chain antibody fragments (scFv) in Saccharomyces

69 echnology, we constructed a library of human single-chain antibody fragments (scFv) to target the pri

70 Single-chain antibody fragments (scFvs) are first isolat

71 arting from large phage display libraries of single-chain antibody fragments (scFvs), the three-stage

72 Here we show that human single-chain antibody fragments (three domain, V(H)/K fo

73 ariables by live-cell microscopic imaging of single-chain antibody fragments against carcinoembryonic

74 We further demonstrated that single-chain antibody fragments against tumor-specific a

75 assemblies for a monoclonal antibody and its single-chain antibody fragments derivatives.

76 It has previously been reported that several single-chain antibody fragments of human origin (scFv) n

77 ity/specificity trade-offs, we have selected single-chain antibody fragments specific for the negativ

78 Diabodies are noncovalent dimers of single-chain antibody fragments that retain the avidity

79 Single-chain antibodies from camelids have served as pow

80 on has been in the area of nanobodies, small single-chain antibodies from camelids or sharks.

81 In this study, we isolated a single-chain antibody from an Indian dromedary camel (IC

82 ells expressing tumor-associated antigens by single-chain antibodies fused to a receptor-binding-defi

83 Furthermore, an ErbB2 single-chain antibody fused with protamine delivered siR

84 pes through the use of a retroviral receptor-single-chain antibody fusion protein.

85 odimer format was used to produce bispecific single chain antibody fusions and monovalent IgGs with m

86 ally inactive murine caspase-3, by screening single-chain antibody (Fv) phage display libraries.

87 f substantial levels of human monoclonal and single chain antibodies (>3 mg and >150 mg, respectively

88 unctional characterization of monoclonal and single-chain antibodies has become just as important as

89 The DO-1 single-chain antibody has been used to construct single-

90 es based on larger complex proteins, such as single chain antibodies, have stimulated interest in the

91 nscription are decorated specifically by the single-chain antibody HF1 and by the nuclear protein PAR

92 as evidenced by changes in the binding of a single-chain antibody highly specific for site B.

93 assessed using monoclonal antibody NV23 and single-chain antibody HJT-R3-A9 to identify both virus-l

94 inding kinetics of a recombinant mAb and its single-chain antibody homolog, single-chain variable fra

95 al growth factor]) or Hu-tagged anti-VEGFR-2 single-chain antibody (Hu-P4G7) and incubating on ice fo

96 ion X-ray structures of three high-affinity, single-chain antibodies in the 14B7 family; 14B7 and two

97 Intrabodies are engineered single-chain antibodies in which the variable domain of

98 Here we show that expression of the DO-1 single-chain antibody in the H1299 cell line results in

99 virus engineered to express a TRAIL-blocking single-chain antibody in the tumour microenvironment ext

100 V-infected cells, including versions where a single-chain antibody is appended to the carboxyl termin

101 This single-chain antibody is the first anti-P. falciparum ef

102 re identified by phage display from a biased single chain antibody library generated from the spleens

103 Yeast panning with a nonimmune human single-chain antibody library identified 34 unique lead

104 We have constructed a membrane-anchored single-chain antibody [m-scFv(HA)] which recognizes a li

105 o different recombinant reporter proteins, a single-chain antibody (M18 scFv) that contains two disul

106 on status of monocytes was determined with a single-chain antibody, MAN-1, which is specific for the

107 Single-chain antibody mutants have been evolved in vitro

108 e second minireview describes application of single chain antibodies (nanobodies) for monitoring and

109 Single-chain antibodies neutralize activity and bind non

110 ignated ITEM4-rGel) and a humanized, dimeric single-chain antibody of ITEM-4 fused to rGel (designate

111 rating the Fc domain and either an anti-CD40 single-chain antibody or CD40L form stable complexes wit

112 We expressed a single chain antibody (p3S5) to KDR with or without the

113 A single-chain antibody phage display library was construc

114 To this end, we developed a single chain antibody (sc1E3) against hIL-1beta that exh

115 nd expressed in high yields, relative to the single chain antibody (SCA) derivative (2 3-fold), in Es

116 tein (gp) and adding a sequence coding for a single chain antibody (SCA) to the Her2/neu receptor.

117 essed a chimeric Sindbis gp which included a single-chain antibody (SCA) directed to the human Her2/n

118 m spleen necrosis virus (SNV) that display a single-chain antibody (scA) on the viral surface.

119 omplementarity determining regions (CDRs) of single-chain antibody (scAb) fragments is demonstrated.

120 e displayed on the viral hemagglutinin (H) a single-chain antibody (scAb) specific for the tumor-asso

121 ed a new receptor by fusing a virus-binding, single-chain antibody (scAb) to intracellular adhesion m

122 t express (1) an intracellular, neutralizing single-chain antibody (scAb) to p21 ras (Ad.K-ras scAb),

123 GLAF-1, a previously undescribed engineered single-chain antibody (scAb).

124 iral vectors derived from SNV that displayed single-chain antibodies (scAs) directed against a carcin

125 We fused a single chain antibody (scFv Ter-119) that binds to mouse

126 ific antibodies by fusing the DNA encoding a single chain antibody (ScFv) after the C terminus (CH3-S

127 ing mesothelin-targeted TR3 variants using a single chain antibody (scFv) delivery format (SS-TR3), w

128 valently but specifically bound to a cognate single chain antibody (scFv).

129 We developed anti-Akt1 single-chain antibodies (scFv) by panning a mouse phage-

130 d rapid production and recovery of idiotypic single-chain antibodies (scFv) derived from each patient

131 First, we engineered a single-chain antibody (scFv) against the c-erbB2 oncopro

132 marker CD38 was constructed in the form of a single-chain antibody (scFv) and (2) display of that scF

133 ification, we constructed an anti-annexin IV single-chain antibody (scFv) and an scFv linked to Crry,

134 l binding interface consisting of a anti-Myc single-chain antibody (ScFv) and its peptide epitope.

135 of immunotoxins containing either the human single-chain antibody (scFv) C6.5 or the murine scFv e23

136 zed a novel complement inhibitor composed of single-chain antibody (scFv) derived from the C2 nAb lin

137 A uniform immunoreagent was prepared from a single-chain antibody (scFv) gene specific for digoxin.

138 o biopanning strategy in which a human phage single-chain antibody (scFv) library was injected into h

139 Using a phage display single-chain antibody (scFv) library, we developed a nov

140 Toward this end, we displayed a single-chain antibody (scFv) specific for the designated

141 ced by genetic fusion of a T84.66 (anti-CEA) single-chain antibody (scFv) to the human IgG1 CH3 domai

142 The corresponding single-chain antibody (scFv) was also prepared, offering

143 Conjugation to the corona of a single-chain antibody (scFv), which binds to the ligand-

144 We use a single-chain antibody (scFv, specific for activated GPII

145 ding epitopes of a panel of eight agonistic, single-chain antibody (scFv-Fc) constructs were determin

146 n order to fulfill this goal, we generated a single-chain antibody (scFv47) from our parental IL13Ral

147 as characterized by stable transfection of a single chain antibody (ScFv5R) against ErbB2 containing

148 stomize the in vivo behavior of an anti-METH single chain antibody (scFv7F9Cys).

149 m for the comparative functional analysis of single-chain antibodies (scFvs) expressed on the plasma

150 ns of rapidly selecting tailored linkers for single-chain antibodies (scFvs) from protein linker libr

151 i mosquitoes expressing m1C3, m4B7, or m2A10 single-chain antibodies (scFvs) have significantly lower

152 een isolated by screening a library of human single-chain antibodies (scFvs) using derivatives of thi

153 Anti-HPV16 E7 intracellular single-chain antibodies (scFvs) were constructed to down

154 venient 1E12 immunoreagent, we constructed a single chain antibody (sFv) using recombinant protein te

155 In particular, single-chain antibodies (sFv) have been reported to fold

156 superfamily, was fused to a gene encoding a single-chain antibody (sFv) against the human transferri

157 In this report, a non-immune human single-chain antibody (sFv) phage display library was us

158 these synthetic receptors was derived from a single-chain antibody (sFv) with specificity for Ad5 kno

159 r, coexpression of an intracellular anti-Rev single-chain antibody (SFv), which has been shown to int

160 roach based upon intracellular expression of single-chain antibodies (sFvs) to achieve modulation of

161 A recombinant PfCHT1/PgCHT2-neutralizing single-chain antibody significantly reduced P. falciparu

162 tilizing Herceptin and its derived humanized single-chain antibody (single-chain fragment variable, d

163 il dimer forming polypeptides was fused to a single chain antibody specific for tumor antigen CD20.

164 d gas-filled MBs were conjugated to either a single-chain antibody specific for activated glycoprotei

165 A single-chain antibody specific for human C5 is a safe an

166 A humanized, recombinant, single-chain antibody specific for human C5, h5G1.1-scFv

167 show that custom superantigens generated by single chain antibody technology permit the study of tol

168 n, we generated a CSPG4-specific fully human single-chain antibody termed scFv-FcC21 and characterize

169 orm for the selection of very high affinity, single-chain antibodies that have tremendous potential a

170 achment of sporozoites to salivary glands; a single-chain antibody that agglutinates sporozoites; or

171 n leukosis viruses (ALV-A), fused to the MR1 single-chain antibody that binds specifically to EGFRvII

172 We have developed a single-chain antibody that is selective for G-quadruplex

173 is-regulatory elements to express an encoded single-chain antibody that prevents the P3A2 protein fro

174 mpetitive selection techniques to generate a single-chain antibody that shows >1000-fold discriminati

175 s approach we have developed a CCR5-specific single-chain antibody that was expressed intracellularly

176 nap) into specific positions of an anti-EGFR single chain antibody to generate an emission wavelength

177 rks, by fusing chromatin-binding proteins or single-chain antibodies to Dam, an Escherichia coli DNA

178 e enhanced by inclusion of sequences such as single-chain antibodies to target the antigen to DCs.

179 cDNA transfection was used to target a single-chain antibody to a specified site such as an org

180 exclusion; this was fused to a CD3-specific single-chain antibody to generate bscEphA2xCD3.

181 F) was expressed, consisting of a His tag, a single-chain antibody to the myeloid antigen CD33, and t

182 A single chain antibody variable domain (scFv) phage displ

183 We generated a single chain antibody variable fragment (scFv) that bind

184 ncAA (CypK) at diverse sites on a displayed single-chain antibody variable fragment (ScFv), in respo

185 and experimental validation of two different single-chain antibody variable fragment libraries that e

186 Single-chain antibody variable fragments (scFv) derived

187 using two different binding scaffold types (single-chain antibody variable fragments and fibronectin

188 we have generated immune-challenged chicken single-chain antibody variable-region fragment (scFv) li

189 rapeutic applications.The therapeutic use of single-chain antibodies (VHHs) is limited by their short

190 A CD7-specific single-chain antibody was conjugated to oligo-9-arginine

191 al vector (33E67) containing a CD33-specific single-chain antibody was generated in an attempt to tar

192 An EphA2-specific single-chain antibody was selected for recognition of an

193 Three different single-chain antibodies were displayed at the extracellu

194 A 27 kDa single chain antibody, which binds to both ligands, serv

195 nfirm the visibility of producing monoclonal single-chain antibodies with a high ability to bind the

196 oid leukemia cells by fusing an anti-IL-1RAP single-chain antibody with streptavidin (tetramer or mon